Table 3.
Overall survival analysis.
| Variable | Alive (%) | 12-month OS (%) | Median OS | p-value (univariate) | p-value (multiv.) |
|---|---|---|---|---|---|
| Overall | 50/71(70.4) | 68.6 | NR | – | – |
| Age | |||||
| <70 years | 38/51 (78.5) | 73.0 | NR | 0.241 | – |
| >70 years | 12/20 (60.0) | 58.3 | NR | ||
| Sex | |||||
| Male | 27/39 (69.2) | 68.0 | NR | 0.877 | – |
| Female | 23/32 (71.9) | 69.3 | NR | ||
| WBC | |||||
| <30 × 109/L | 43/60 (71.7) | 70.0 | NR | 0.490 | – |
| >30 × 109/L | 7/11 (63.6) | 62.3 | NR | ||
| Marrow blasts | |||||
| <30% | 17/22 (77.3) | 76.7 | NR | 0.371 | – |
| >30% | 33/49 (67.3) | 64.9 | NR | ||
| Previous HMA | |||||
| No | 16/54 (70.4) | 68.9 | NR | 0.945 | – |
| Yes | 15/17 (70.6) | 69.1 | NR | ||
| NPM1 | |||||
| Wild type | 43/63 (68.3) | 66.6 | NR | 0.162 | – |
| Mutated | 5/5 (100) | 100 | NR | ||
| FLT3-ITD | |||||
| Negative | 45/64 (70.3) | 68.3 | NR | 0.570 | – |
| Positive | 3/5 (60.0) | 60.0 | NR | ||
| TP53 | |||||
| Wild type | 20/24 (83.3) | 83.1 | NR | 0.081 | 0.570 |
| Mutated | 7/13 (53.8) | 51.9 | NR | ||
| Karyotype | |||||
| Fav./Int. | 31/39 (79.5) | 78.6 | NR | 0.049 | 0.051 |
| Poor | 19/32 (59.4) | 56.6 | NR | ||
| Therapy related | |||||
| No | 35/49 (71.4) | 68.7 | NR | 0.717 | – |
| Yes | 15/22 (68.2) | 68.2 | NR | ||
| ELN 2017 | |||||
| Low/Int. | 26/32 (88.9) | 79.9 | NR | 0.073 | 0.071 |
| High | 24/39 (64.7) | 59.5 | NR | ||
| MRD TP1 | |||||
| Negative | 11/15 (73.3) | 71.1 | NR | 0.414 | – |
| Positive | 21/25 (84.0) | 84.0 | NR | ||